An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features

Chi Un Pae, Prakash S. Masand, Kathleen Peindl, Paolo Mannelli, Changsu Han, David M. Marks, Ashwin A. Patkar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: Although selective serotonin reuptake inhibitors (SSRIs) have become the standard of care for the treatment of major depressive disorder (MDD), limited data exist to support their use in MDD with atypical features. The current study investigates the efficacy of the SSRI escitalopram in an 8-week, open-label, flexible-dose, rater-blinded trial. Method: Seventeen DSM-IV MDD subjects aged from 18 through 65 years completed screening procedures, provided informed consent, and went through a minimum 2-week washout from preexisting antidepressants except fluoxetine (a minimum 4-week washout). They subsequently received escitalopram (10-20 mg/day) for 8 weeks. The primary efficacy measure was a change in score from baseline to end of treatment on the Structured Interview Guide for the Hamilton Rating Scale for Depression-Seasonal Affective Disorder version (SIGH-SAD), which includes a set of items for atypical symptoms. Secondary efficacy measures were defined as changes from baseline to end of treatment in scores on the SIGH-SAD atypical symptoms subscale (consisting of 8 items specific to atypical features), Beck Depression Inventory-II, Beck Anxiety Inventory, Sheehan Disability Scale, and Epworth Sleepiness Questionnaire. The study was conducted from October 2005 to November 2006. Results: The mean age was 43.9 years, and 70.6% of subjects were women. The dropout rate was 11.8% (N = 2/17). The mean dose of escitalopram was 18.3 mg/day. The total SIGH-SAD score (mean ± SD) reduced by 53.8% from baseline (33.3 ± 8.2) to end of treatment (15.4 ± 9.4) (t = 4.24, p < .001). The atypical symptoms subscale score reduced by 44.5% from baseline (11.0 ± 4.3) to end of treatment (6.1 ± 2.8) (t = 5.26, p = .001). Ten subjects (62.5%) were classified as responders at end of treatment as defined by ≥ 50% reduction in SIGH-SAD total score. Overall, escitalopram was well tolerated. Conclusions: Our preliminary study indicates that escitalopram may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine the efficacy of escitalopram in this disorder. Trial Registration: clinicaltrials.gov Identifier: NCT00610506.

Original languageEnglish
Pages (from-to)205-210
Number of pages6
JournalPrimary Care Companion to the Journal of Clinical Psychiatry
Volume10
Issue number3
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

Citalopram
Major Depressive Disorder
Serotonin Uptake Inhibitors
Therapeutics
Seasonal Affective Disorder
Depression
Equipment and Supplies
Fluoxetine
Standard of Care
Informed Consent
Diagnostic and Statistical Manual of Mental Disorders
Antidepressive Agents
Anxiety
Placebos
Interviews

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. / Pae, Chi Un; Masand, Prakash S.; Peindl, Kathleen; Mannelli, Paolo; Han, Changsu; Marks, David M.; Patkar, Ashwin A.

In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 10, No. 3, 01.01.2008, p. 205-210.

Research output: Contribution to journalArticle

Pae, Chi Un ; Masand, Prakash S. ; Peindl, Kathleen ; Mannelli, Paolo ; Han, Changsu ; Marks, David M. ; Patkar, Ashwin A. / An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. In: Primary Care Companion to the Journal of Clinical Psychiatry. 2008 ; Vol. 10, No. 3. pp. 205-210.
@article{6189d99958b74f9b8e782c7e4630fdf8,
title = "An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features",
abstract = "Objectives: Although selective serotonin reuptake inhibitors (SSRIs) have become the standard of care for the treatment of major depressive disorder (MDD), limited data exist to support their use in MDD with atypical features. The current study investigates the efficacy of the SSRI escitalopram in an 8-week, open-label, flexible-dose, rater-blinded trial. Method: Seventeen DSM-IV MDD subjects aged from 18 through 65 years completed screening procedures, provided informed consent, and went through a minimum 2-week washout from preexisting antidepressants except fluoxetine (a minimum 4-week washout). They subsequently received escitalopram (10-20 mg/day) for 8 weeks. The primary efficacy measure was a change in score from baseline to end of treatment on the Structured Interview Guide for the Hamilton Rating Scale for Depression-Seasonal Affective Disorder version (SIGH-SAD), which includes a set of items for atypical symptoms. Secondary efficacy measures were defined as changes from baseline to end of treatment in scores on the SIGH-SAD atypical symptoms subscale (consisting of 8 items specific to atypical features), Beck Depression Inventory-II, Beck Anxiety Inventory, Sheehan Disability Scale, and Epworth Sleepiness Questionnaire. The study was conducted from October 2005 to November 2006. Results: The mean age was 43.9 years, and 70.6{\%} of subjects were women. The dropout rate was 11.8{\%} (N = 2/17). The mean dose of escitalopram was 18.3 mg/day. The total SIGH-SAD score (mean ± SD) reduced by 53.8{\%} from baseline (33.3 ± 8.2) to end of treatment (15.4 ± 9.4) (t = 4.24, p < .001). The atypical symptoms subscale score reduced by 44.5{\%} from baseline (11.0 ± 4.3) to end of treatment (6.1 ± 2.8) (t = 5.26, p = .001). Ten subjects (62.5{\%}) were classified as responders at end of treatment as defined by ≥ 50{\%} reduction in SIGH-SAD total score. Overall, escitalopram was well tolerated. Conclusions: Our preliminary study indicates that escitalopram may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine the efficacy of escitalopram in this disorder. Trial Registration: clinicaltrials.gov Identifier: NCT00610506.",
author = "Pae, {Chi Un} and Masand, {Prakash S.} and Kathleen Peindl and Paolo Mannelli and Changsu Han and Marks, {David M.} and Patkar, {Ashwin A.}",
year = "2008",
month = "1",
day = "1",
doi = "10.4088/PCC.v10n0305",
language = "English",
volume = "10",
pages = "205--210",
journal = "The primary care companion for CNS disorders",
issn = "1523-5998",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

TY - JOUR

T1 - An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features

AU - Pae, Chi Un

AU - Masand, Prakash S.

AU - Peindl, Kathleen

AU - Mannelli, Paolo

AU - Han, Changsu

AU - Marks, David M.

AU - Patkar, Ashwin A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Objectives: Although selective serotonin reuptake inhibitors (SSRIs) have become the standard of care for the treatment of major depressive disorder (MDD), limited data exist to support their use in MDD with atypical features. The current study investigates the efficacy of the SSRI escitalopram in an 8-week, open-label, flexible-dose, rater-blinded trial. Method: Seventeen DSM-IV MDD subjects aged from 18 through 65 years completed screening procedures, provided informed consent, and went through a minimum 2-week washout from preexisting antidepressants except fluoxetine (a minimum 4-week washout). They subsequently received escitalopram (10-20 mg/day) for 8 weeks. The primary efficacy measure was a change in score from baseline to end of treatment on the Structured Interview Guide for the Hamilton Rating Scale for Depression-Seasonal Affective Disorder version (SIGH-SAD), which includes a set of items for atypical symptoms. Secondary efficacy measures were defined as changes from baseline to end of treatment in scores on the SIGH-SAD atypical symptoms subscale (consisting of 8 items specific to atypical features), Beck Depression Inventory-II, Beck Anxiety Inventory, Sheehan Disability Scale, and Epworth Sleepiness Questionnaire. The study was conducted from October 2005 to November 2006. Results: The mean age was 43.9 years, and 70.6% of subjects were women. The dropout rate was 11.8% (N = 2/17). The mean dose of escitalopram was 18.3 mg/day. The total SIGH-SAD score (mean ± SD) reduced by 53.8% from baseline (33.3 ± 8.2) to end of treatment (15.4 ± 9.4) (t = 4.24, p < .001). The atypical symptoms subscale score reduced by 44.5% from baseline (11.0 ± 4.3) to end of treatment (6.1 ± 2.8) (t = 5.26, p = .001). Ten subjects (62.5%) were classified as responders at end of treatment as defined by ≥ 50% reduction in SIGH-SAD total score. Overall, escitalopram was well tolerated. Conclusions: Our preliminary study indicates that escitalopram may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine the efficacy of escitalopram in this disorder. Trial Registration: clinicaltrials.gov Identifier: NCT00610506.

AB - Objectives: Although selective serotonin reuptake inhibitors (SSRIs) have become the standard of care for the treatment of major depressive disorder (MDD), limited data exist to support their use in MDD with atypical features. The current study investigates the efficacy of the SSRI escitalopram in an 8-week, open-label, flexible-dose, rater-blinded trial. Method: Seventeen DSM-IV MDD subjects aged from 18 through 65 years completed screening procedures, provided informed consent, and went through a minimum 2-week washout from preexisting antidepressants except fluoxetine (a minimum 4-week washout). They subsequently received escitalopram (10-20 mg/day) for 8 weeks. The primary efficacy measure was a change in score from baseline to end of treatment on the Structured Interview Guide for the Hamilton Rating Scale for Depression-Seasonal Affective Disorder version (SIGH-SAD), which includes a set of items for atypical symptoms. Secondary efficacy measures were defined as changes from baseline to end of treatment in scores on the SIGH-SAD atypical symptoms subscale (consisting of 8 items specific to atypical features), Beck Depression Inventory-II, Beck Anxiety Inventory, Sheehan Disability Scale, and Epworth Sleepiness Questionnaire. The study was conducted from October 2005 to November 2006. Results: The mean age was 43.9 years, and 70.6% of subjects were women. The dropout rate was 11.8% (N = 2/17). The mean dose of escitalopram was 18.3 mg/day. The total SIGH-SAD score (mean ± SD) reduced by 53.8% from baseline (33.3 ± 8.2) to end of treatment (15.4 ± 9.4) (t = 4.24, p < .001). The atypical symptoms subscale score reduced by 44.5% from baseline (11.0 ± 4.3) to end of treatment (6.1 ± 2.8) (t = 5.26, p = .001). Ten subjects (62.5%) were classified as responders at end of treatment as defined by ≥ 50% reduction in SIGH-SAD total score. Overall, escitalopram was well tolerated. Conclusions: Our preliminary study indicates that escitalopram may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine the efficacy of escitalopram in this disorder. Trial Registration: clinicaltrials.gov Identifier: NCT00610506.

UR - http://www.scopus.com/inward/record.url?scp=45849145733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849145733&partnerID=8YFLogxK

U2 - 10.4088/PCC.v10n0305

DO - 10.4088/PCC.v10n0305

M3 - Article

VL - 10

SP - 205

EP - 210

JO - The primary care companion for CNS disorders

JF - The primary care companion for CNS disorders

SN - 1523-5998

IS - 3

ER -